Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN22734699
ISRCTN22734699
Active, not recruiting
未知

QuicDNA - Integration of Liquid Biopsy into Lung Cancer Diagnostic

Aneurin Bevan University Health Board0 sites1,260 target enrollmentJune 19, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients with suspected stage III (excluding radical treatment) and IV lung cancer based on computer tomography (CT scan) and have tissue biopsy (SOC) diagnostic testing plannedCancer

Overview

Phase
未知
Intervention
Not specified
Conditions
Patients with suspected stage III (excluding radical treatment) and IV lung cancer based on computer tomography (CT scan) and have tissue biopsy (SOC) diagnostic testing planned
Sponsor
Aneurin Bevan University Health Board
Enrollment
1260
Status
Active, not recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 19, 2023
End Date
January 31, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Be willing and able to provide written informed consent for the study
  • •2\. Age 16 years or over on day of signing informed consent
  • •3\. Have radiologically suspected advanced stage III (excluding radical treatment) and stage IV lung cancer from CT scan as evaluated and reported by clinical team and/or a radiologist
  • •4\. Consent to have a genetic analysis performed on ctDNA from their blood sample
  • •5\. Have a performance status of 0 or 3 on the ECOG Performance Scale

Exclusion Criteria

  • •1\. Is unable or unwilling to comply with study procedures
  • •2\. Stage I, II, or III suspected lung cancer that qualifies for radical treatment (surgery, radical radiotherapy or chemoradiotherapy)
  • •3\. Have any known concurrent malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer ResectionNon Small Cell Lung Cancer
NCT05254782University Health Network, Toronto360
Not yet recruiting
Not Applicable
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² StudyLung Cancer
NCT06105177Catharina Ziekenhuis Eindhoven800
Active, not recruiting
Not Applicable
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer
NCT04703153Lucence Health Inc.151
Recruiting
Phase 2
Using ctDNA to Determine Therapies for Lung CancerNon Small Cell Lung CancerComplete Surgical ResectionCirculating Tumor DNA
NCT04966663University Health Network, Toronto66
Active, not recruiting
Not Applicable
Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)Advanced Solid Tumor
NCT06367751University Hospital, Basel, Switzerland159